Literature DB >> 12773178

Toll-like receptor 4 signalling: new perspectives on a complex signal-transduction problem.

S N Vogel1, M Fenton.   

Abstract

We previously reported that Toll-like receptor-2 (TLR2) agonists induce expression of a more limited repertoire of pro-inflammatory genes than TLR4 agonists. Murine macrophages stimulated with the TLR4 agonist, Escherichia coli lipopolysaccharide, induced signal transducer and activator of transcription 1 ('STAT1') tyrosine phosphorylation that was secondary to the autocrine/paracrine action of interferon (IFN)-beta, an immediate early gene. In contrast, TLR2 agonists failed to activate IFN-beta gene expression. TLR4-induced IFN-beta mRNA was found to be MyD88- and PKR (double-stranded RNA-dependent protein kinase)-independent, but TIRAP (Toll/interleukin-1 receptor domain-containing adapter protein)/Mal (MyD88-adapter-like)-dependent. In the present paper, we outline the recent controversy over the role of TIRAP/Mal in TLR2 and TLR4 signalling in the context of the current molecular tools used for such studies. Collectively, our findings provide the first mechanistic basis for differential patterns of gene expression activated by TLR4 and TLR2 agonists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12773178     DOI: 10.1042/bst0310664

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  18 in total

1.  Bacterial lipoprotein TLR2 agonists broadly modulate endothelial function and coagulation pathways in vitro and in vivo.

Authors:  Hae-Sook Shin; Fengyun Xu; Aranya Bagchi; Elizabeth Herrup; Arun Prakash; Catherine Valentine; Hrishikesh Kulkarni; Kevin Wilhelmsen; Shaw Warren; Judith Hellman
Journal:  J Immunol       Date:  2010-12-17       Impact factor: 5.422

2.  Toll-like receptors-2 and 4 are overexpressed in an experimental model of particle-induced osteolysis.

Authors:  Roberto D Valladares; Christophe Nich; Stefan Zwingenberger; Chenguang Li; Katherine R Swank; Emmanuel Gibon; Allison J Rao; Zhenyu Yao; Stuart B Goodman
Journal:  J Biomed Mater Res A       Date:  2013-10-07       Impact factor: 4.396

Review 3.  Epigenetics, bioenergetics, and microRNA coordinate gene-specific reprogramming during acute systemic inflammation.

Authors:  Charles E McCall; Mohamed El Gazzar; Tiefu Liu; Vidula Vachharajani; Barbara Yoza
Journal:  J Leukoc Biol       Date:  2011-05-24       Impact factor: 4.962

4.  Inflammatory effects of Edwardsiella ictaluri lipopolysaccharide modifications in catfish gut.

Authors:  Javier Santander; Jacquelyn Kilbourne; Jie-Yeun Park; Taylor Martin; Amanda Loh; Ignacia Diaz; Robert Rojas; Cristopher Segovia; Dale DeNardo; Roy Curtiss
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

5.  The myristoylation of TRIF-related adaptor molecule is essential for Toll-like receptor 4 signal transduction.

Authors:  Daniel C Rowe; Anne F McGettrick; Eicke Latz; Brian G Monks; Nicholas J Gay; Masahiro Yamamoto; Shizuo Akira; Luke A O'Neill; Katherine A Fitzgerald; Douglas T Golenbock
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-07       Impact factor: 11.205

6.  Targeting TLR4 signaling by TLR4 Toll/IL-1 receptor domain-derived decoy peptides: identification of the TLR4 Toll/IL-1 receptor domain dimerization interface.

Authors:  Vladimir Y Toshchakov; Henryk Szmacinski; Leah A Couture; Joseph R Lakowicz; Stefanie N Vogel
Journal:  J Immunol       Date:  2011-03-14       Impact factor: 5.422

7.  Role of TLR-4 in liver macrophage and endothelial cell responsiveness during acute endotoxemia.

Authors:  Li C Chen; Ronald E Gordon; Jeffrey D Laskin; Debra L Laskin
Journal:  Exp Mol Pathol       Date:  2007-09-14       Impact factor: 3.362

8.  Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis.

Authors:  Jinsheng Guo; Scott L Friedman
Journal:  Fibrogenesis Tissue Repair       Date:  2010-10-21

9.  Association between TLR4 and TLR9 gene polymorphisms with development of pulmonary tuberculosis in Zahedan, southeastern Iran.

Authors:  Danial Jahantigh; Saeedeh Salimi; Roya Alavi-Naini; Abolfazl Emamdadi; Hamid Owaysee Osquee; Farzaneh Farajian Mashhadi
Journal:  ScientificWorldJournal       Date:  2013-05-26

10.  Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.

Authors:  Nana O Wilson; Wesley Solomon; Leonard Anderson; John Patrickson; Sidney Pitts; Vincent Bond; Mingli Liu; Jonathan K Stiles
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.